Ajanta Pharma Ltd
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
- Market Cap ₹ 32,292 Cr.
- Current Price ₹ 2,585
- High / Low ₹ 3,486 / 2,022
- Stock P/E 35.1
- Book Value ₹ 290
- Dividend Yield 1.39 %
- ROCE 33.3 %
- ROE 25.6 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 44.1%
Cons
- Stock is trading at 8.91 times its book value
- Promoter holding has decreased over last 3 years: -4.22%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Healthcare BSE MidCap Nifty 500 Nifty MidSmallcap 400 BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,208 | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | |
840 | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,389 | |
Operating Profit | 369 | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,260 |
OPM % | 31% | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% |
14 | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 94 | |
Interest | 9 | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 |
Depreciation | 44 | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 |
Profit before tax | 330 | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 |
Tax % | 29% | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% |
234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | |
EPS in Rs | 17.75 | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 |
Dividend Payout % | 15% | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 12% |
3 Years: | 12% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 14% |
3 Years: | 9% |
TTM: | 14% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 21% |
3 Years: | 30% |
1 Year: | 8% |
Return on Equity | |
---|---|
10 Years: | 24% |
5 Years: | 23% |
3 Years: | 22% |
Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 |
Reserves | 576 | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,600 |
130 | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 31 | |
226 | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 898 | |
Total Liabilities | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,554 |
279 | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,742 | |
CWIP | 94 | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 |
Investments | 63 | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 482 |
513 | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,154 | |
Total Assets | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,554 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
212 | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | 792 | 785 | 1,157 | |
-188 | -158 | -209 | -383 | -256 | -223 | -224 | -282 | -74 | -560 | 65 | -377 | |
-20 | -105 | -117 | -202 | -0 | -147 | -129 | -318 | -460 | -108 | -1,051 | -733 | |
Net Cash Flow | 4 | 16 | -0 | 24 | 25 | 4 | 104 | -24 | 28 | 124 | -201 | 47 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 61 | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 | 96 |
Inventory Days | 164 | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 | 252 |
Days Payable | 132 | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 | 125 |
Cash Conversion Cycle | 94 | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 | 223 |
Working Capital Days | 57 | 61 | 90 | 65 | 103 | 119 | 116 | 127 | 141 | 84 | 120 | 143 |
ROCE % | 55% | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% | 33% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16h
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Audio recording of Q4 FY2025 earnings call uploaded on Ajanta Pharma website.
-
PFA Intimation W.R.T Cancellation Of Esops
2d - Cancellation of 1,000 ESOPs under 2019 Share Based Incentive Plan.
-
Announcement under Regulation 30 (LODR)-Meeting Updates
2d - Re-appointment of Executive Director and auditors for FY 2025-26 approved by Ajanta Pharma board.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Re-appointment of Executive Director and auditors for FY 2025-26 approved by Ajanta Pharma board.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
Concalls
-
Feb 2025Transcript PPT
-
Oct 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Oct 2023TranscriptPPTREC
-
Jul 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Aug 2022TranscriptPPT
-
Jan 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
Apr 2021TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Apr 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Oct 2018TranscriptNotesPPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Oct 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Oct 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
Apr 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]